445 related articles for article (PubMed ID: 31537445)
1. A Porcine circovirus type 2b (PCV2b)-based experimental vaccine is effective in the PCV2b-Mycoplasma hyopneumoniae coinfection pig model.
Opriessnig T; Castro AMMG; Karuppanan AK; Gauger PC; Halbur PG; Matzinger SR; Meng XJ
Vaccine; 2019 Oct; 37(44):6688-6695. PubMed ID: 31537445
[TBL] [Abstract][Full Text] [Related]
2. Porcine circovirus type 2a or 2b based experimental vaccines provide protection against PCV2d/porcine parvovirus 2 co-challenge.
Opriessnig T; Karuppannan AK; Halbur PG; Calvert JG; Nitzel GP; Matzinger SR; Meng XJ
Vaccine; 2020 Feb; 38(8):1975-1981. PubMed ID: 31974016
[TBL] [Abstract][Full Text] [Related]
3. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions.
Opriessnig T; Xiao CT; Halbur PG; Gerber PF; Matzinger SR; Meng XJ
Vaccine; 2017 Jan; 35(2):248-254. PubMed ID: 27919634
[TBL] [Abstract][Full Text] [Related]
4. A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV and PPV infection.
Opriessnig T; O'Neill K; Gerber PF; de Castro AM; Gimenéz-Lirola LG; Beach NM; Zhou L; Meng XJ; Wang C; Halbur PG
Vaccine; 2013 Jan; 31(3):487-94. PubMed ID: 23174198
[TBL] [Abstract][Full Text] [Related]
5. Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2.
Opriessnig T; Gerber PF; Xiao CT; Halbur PG; Matzinger SR; Meng XJ
Vaccine; 2014 Jul; 32(34):4342-8. PubMed ID: 24929119
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a porcine circovirus type 2a (PCV2a) vaccine efficacy against experimental PCV2a, PCV2b, and PCV2d challenge.
Park KH; Oh T; Yang S; Cho H; Kang I; Chae C
Vet Microbiol; 2019 Apr; 231():87-92. PubMed ID: 30955830
[TBL] [Abstract][Full Text] [Related]
7. A commercial PCV2a-based vaccine is effective in protection from experimental challenge of PCV2 mutant with two amino acids elongation in capsid protein.
Guo LJ; Fu YJ; Huang LP; Wang YP; Wei YW; Wu HL; Liu CM
Vaccine; 2015 Jul; 33(31):3752-7. PubMed ID: 26051516
[TBL] [Abstract][Full Text] [Related]
8. An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge model.
Opriessnig T; Gomes-Neto JC; Hemann M; Shen HG; Beach NM; Huang Y; Halbur PG; Meng XJ
Microbiol Immunol; 2011 Dec; 55(12):863-73. PubMed ID: 21951266
[TBL] [Abstract][Full Text] [Related]
9. Efficacy comparison of commercial porcine circovirus type 2 (PCV2) and
Yang S; Park SJ; Oh T; Cho H; Chae C
Can J Vet Res; 2020 Oct; 84(4):272-282. PubMed ID: 33012976
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines in a herd with concurrent circulation of PCV2b and mutant PCV2b.
Jeong J; Park C; Choi K; Chae C
Vet Microbiol; 2015 May; 177(1-2):43-52. PubMed ID: 25790733
[TBL] [Abstract][Full Text] [Related]
11. Inactivated chimeric porcine circovirus (PCV) 1-2 vaccines based on genotypes 2b and 2d exhibit similar immunological effectiveness in protecting pigs against challenge with PCV2b strain 0233.
Li J; Yu T; Zhang F; Wang X; Zhou J; Gao X; Gao S; Liu X
Arch Virol; 2017 Jan; 162(1):235-246. PubMed ID: 27722993
[TBL] [Abstract][Full Text] [Related]
12. A new single-dose bivalent vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae elicits protective immunity and improves growth performance under field conditions.
Jeong J; Park C; Choi K; Chae C
Vet Microbiol; 2016 Jan; 182():178-86. PubMed ID: 26711046
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a new bivalent vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae (Fostera™ PCV MH) under experimental conditions.
Park C; Jeong J; Choi K; Chae C
Vaccine; 2016 Jan; 34(2):270-275. PubMed ID: 26626212
[TBL] [Abstract][Full Text] [Related]
14. Interaction of porcine circovirus type 2 and Mycoplasma hyopneumoniae vaccines on dually infected pigs.
Seo HW; Park SJ; Park C; Chae C
Vaccine; 2014 May; 32(21):2480-6. PubMed ID: 24631087
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy of a trivalent vaccine mixture against a triple challenge with Mycoplasma hyopneumoniae, PCV2, and PRRSV and the efficacy comparison of the respective monovalent vaccines against a single challenge.
Oh T; Park KH; Yang S; Jeong J; Kang I; Park C; Chae C
BMC Vet Res; 2019 Oct; 15(1):342. PubMed ID: 31619295
[TBL] [Abstract][Full Text] [Related]
16. A commercial vaccine based on PCV2a and an experimental vaccine based on a variant mPCV2b are both effective in protecting pigs against challenge with a 2013 U.S. variant mPCV2b strain.
Opriessnig T; Gerber PF; Xiao CT; Mogler M; Halbur PG
Vaccine; 2014 Jan; 32(2):230-7. PubMed ID: 24269319
[TBL] [Abstract][Full Text] [Related]
17. A chimeric virus created by DNA shuffling of the capsid genes of different subtypes of porcine circovirus type 2 (PCV2) in the backbone of the non-pathogenic PCV1 induces protective immunity against the predominant PCV2b and the emerging PCV2d in pigs.
Matzinger SR; Opriessnig T; Xiao CT; Catanzaro N; Beach NM; Slade DE; Nitzel GP; Meng XJ
Virology; 2016 Nov; 498():82-93. PubMed ID: 27564544
[TBL] [Abstract][Full Text] [Related]
18. Cellular and humoral immunity following vaccination with two different PCV2 vaccines (containing PCV2a or PCV2a/PCV2b) and challenge with virulent PCV2d.
Venegas-Vargas C; Taylor LP; Foss DL; Godbee TK; Philip R; Bandrick M
Vaccine; 2021 Sep; 39(39):5615-5625. PubMed ID: 34420789
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and phylogenetic analysis of the current porcine circovirus 2 genotypes after implementation of widespread vaccination programmes in the USA.
Shen HG; Halbur PG; Opriessnig T
J Gen Virol; 2012 Jun; 93(Pt 6):1345-1355. PubMed ID: 22398315
[TBL] [Abstract][Full Text] [Related]
20. A live-attenuated chimeric porcine circovirus type 2 (PCV2) vaccine is transmitted to contact pigs but is not upregulated by concurrent infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV) and is efficacious in a PCV2b-PRRSV-PPV challenge model.
Opriessnig T; Shen HG; Pal N; Ramamoorthy S; Huang YW; Lager KM; Beach NM; Halbur PG; Meng XJ
Clin Vaccine Immunol; 2011 Aug; 18(8):1261-8. PubMed ID: 21653745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
